Here we report the isolation of carboxypeptidases A1 and A2 (CPA1 and CPA2) from the rat mesenteric arterial bed perfusate, which were found to be identical with their pancreatic counterparts. Angiotensin (Ang) I, Ang II, Ang-(1-9) and Ang-(1-12) were differentially processed by these enzymes, worthy mentioning the peculiar CPA1-catalyzed conversion of Ang II to Ang-(1-7) and the CPA2-mediated formation of Ang I from Ang-(1-12). We detected gene transcripts for CPA1 and CPA2 in mesentery and other extrapancreatic tissues, indicating that these CPAs might play a role in the renin-angiotensin system in addition to their functions as digestive enzymes.
Introduction
The renin-angiotensin system (RAS) consists of a number of peptide ligands and receptors whose distributions vary between species and, within species between individuals, according to the developmental stage, integrity and functional status of their different tissues. Such complexity reflects the many physiological and physiopathological functions carried out by the RAS which, in addition, require a network of intertwined enzymatic pathways to produce the different angiotensin (Ang) peptides that act as effector molecules of the system. At first the RAS was thought as a typical endocrine system in which the effector hormone Ang II would be formed by a two-step reaction, whereby the Ang I initially released from angiotensinogen by circulating renin would then be converted into Ang II by the action of the metalloprotease angiotensin converting enzyme (ACE). Despite the central role of this angiotensinogen-renin-ACE-Ang II axis for many of the functions carried out by the RAS, it became clear over the years that in some tissues Ang II could also be formed from Ang I by ACEindependent [5] or from Ang-(1-12) by renin-independent [20] pathways. The serine protease chymase, for instance, is the major enzyme that converts Ang I to Ang II in the human heart [32] , while in the rat heart infused with Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) this enzyme appears to be responsible for most of the hemodynamic effects caused by the released Ang II [26] . Moreover, several Ang peptides shorter than Ang II were described as functionally active components of the RAS [9] , implying the participation of proteases other than ACE to account for the required processing of the respective Ang precursors. Among these, neprilysin generates C-terminally modified Ang fragments, releasing Ang-(1-7) from both Ang I and Ang-(1-9) [28] . A variety of enzymes displaying CPA-like activity have also been implicated in the proteolytic processing of Ang peptides. Cathepsin A of human heart generates Ang-(1-7) and Ang-(1-9), two molecules that act as bradykinin potentiator and ACE inhibitor, respectively [12] . Besides, in the human heart a mast cell CPA-like enzyme has been proposed to regulate the local Ang II formation by releasing the ACE inhibitor Ang-(1-9) into the interstitial fluid [13] . In porcine kidney, cathepsin A seems to participate in the local RAS by forming Ang-(1-9) and Ang II, but not Ang-(1-7) [19] . The identification of ACE2 by genomic approaches as a human homolog of ACE that displays carboxypeptidase activity [6, 30] reinforces the current awareness of the functional complexity of the multifaceted, multicomponent RAS. ACE2 can act upon Ang I and Ang II to generate Ang-(1-9) and Ang-(1-7), respectively, two metabolites that 0196-9781/© 2011 Elsevier Inc. doi:10.1016/j.peptides.2011.12.001
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oppose the action of Ang II either by regulating the formation of Ang II by ACE [13, 29] or triggering opposing biological responses mediated by distinct receptors [7] . In previous investigations we showed that the perfused ex vivo preparation of the rat mesenteric arterial bed (MAB), known as the McGregor's preparation [18] , secretes a multiplicity of Ang I-and Ang II-processing CPs potentially relevant to the metabolism of vasoactive and other peptides in the rat mesentery [22, 25] . To further characterize these enzymes, in the present study we aimed at: (1) identifying the CPs that constitute major Ang processing pathways in the rat MAB perfusate; (2) investigating the enzymatic activities of purified CPs obtained from rat MAB perfusate toward Ang I, Ang-(1-9), Ang II and Ang-(1-12); and (3) determining the expression profile of the mRNAs for the different CPAs in representative rat tissues, in which RAS is believed to play a functional role in the local circulatory system.
Material and methods

Material
Potato carboxypeptidase inhibitor (PCI), N-carbobenzyloxyVal-Phe (Z-Val-Phe), Ang I (Asp 1 -Arg-Val-Tyr-Ile-His-Pro-Phe-HisLeu 10 ), Ang II (Asp 1 -Arg-Val-Tyr-Ile-His-Pro-Phe 8 ), bradykinin (BK; Arg 1 -Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg 9 ), dl-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid (MGTA),1,10-phenanthroline, soybean trypsin inhibitor (SBTI) and DEAE-Sepharose fast flow were obtained from Sigma Chemical Co. (St. Louis, MO). Ang-(1-9) and Ang-(1-12) were synthesized by conventional Fmoc solid phase peptide synthesis [8] and purified by C-18 reversed-phase HPLC. Packed MonoQ 5/5 column was from Pharmacia Fine Chemicals (Uppsala, Sweden). All other reagents used were of analytical grade.
Isolation of the rat mesentery and harvesting of MAB perfusate
All animal protocols were approved by the School of Medicine of Ribeirão Preto Institutional Animal Care and Use Committees. The surgical procedures for the isolation of the rat mesentery and the perfusion of the respective arterial system with Krebs solution were performed as previously described [24] . High molecular mass substances of pooled rat MAB perfusates were concentrated 80-fold by ultrafiltration under N 2 pressure using Amicon YM-10 membrane and stored at 4 • C until use.
Enzyme assays
All rat MAB CPA assays were carried out at 37 • C by incubating the specified substrate with the enzyme in 150 L of 20 mM Tris-HCl buffer pH 8.1, and the reactions terminated by the addition of 10 L of 5% TFA. One unit of enzyme activity was defined as the amount of enzyme capable of releasing 1.0 mol of product per min from the indicated substrate solution; unless otherwise specified, the concentration of Z-Val-Phe in the reaction mixture was 10 mM and those of angiotensin peptides and bradykinin were 0.25 mM. The cleavage of Z-Val-Phe and other peptides was assessed by reversed-phase HPLC analysis on a Shimadzu SCL-6B equipment fitted with a 0.46 cm × 15 cm Vydac ODS column; Phe and peptide fragments were eluted with a linear gradient of acetonitrile concentration ranging from 0 to 10% (10 min) and 12 to 45% (33 min) in 0.1% TFA, respectively, at a flow rate of 1.0 mL/min, and monitored by absorbance at 215 nm; peptides were identified by comparison of their retention times with those of the respective cognate synthetic peptides. Whenever used, the protease inhibitors MGTA, PCI, 1,10-phenanthroline and SBTI were preincubated for 10 min, at the indicated concentrations, with the enzyme solution.
Estimation of kinetic constants
To estimate the kinetic parameters for the rat CPA1 and CPA2-catalyzed hydrolyses of Ang II, initial velocities were determined, in duplicate, under conditions adjusted to limit substrate consumption to less than 10% of its initial concentration. Thus, samples of rat MAB CPA1 (0.45 mU, based on Z-Val-Phe hydrolysis) and CPA2 (9.2 mU, based on Z-Val-Phe hydrolysis) were incubated at 37 • C for 20 min and 150 min, respectively, in a final volume of 0.5 mL of 20 mM Tris-HCl buffer, pH 8.1, with seven concentrations of Ang II ranging from 10 to 200 M for CPA1 and 25 to 500 M for CPA2. Reactions were terminated by the addition of 20 L of 5% TFA and the respective products were assayed by HPLC analysis. The kinetic parameters Michaelis constant, K m , and catalytic constant, k cat , were derived from initial velocity data (N = 2) using GraFit version 3.0 software [15] , which performed non-linear regression analysis of data plotted according to the Michaelis-Menten equation.
Enzyme purification
The initial step in the purification of the two major rat MAB Angprocessing carboxypeptidases was carried out by anion exchange chromatography, as detailed in a previous work [25] . Further purification leading to the isolation of CPA1 and CPA2 was achieved by chromatographing the major Ang-(1-7)-forming enzyme and the most conspicuous Ang-(1-9)-forming enzyme of the rat MAB perfusate [25] , respectively, over MonoQ 5/5 column; each chromatography was developed at room temperature with a flow rate of 6 mL/h using 20 mL of the indicated linear gradient of NaCl concentration in 20 mM Tris-HCl buffer, pH 8.1. Enzyme activity was measured using either Z-Val-Phe or Ang II as the substrate, as indicated in the respective figures. Contaminant kininase activity was removed from pooled CPA-containing fractions by affinity chromatography over arginine-Sepharose column (1.5 cm × 3.5 cm) equilibrated and developed with 1 M NaCl solution buffered with 30 mM Tris-HCl, pH 7.2, as previously described [23] . The CPA-containing fractions were pooled and stored at 4 • C until use.
SDS-PAGE
Analytical SDS-PAGE was carried out on 15% polyacrylamide gels essentially as described [14] , using a Mini-Protean 3 electrophoresis system (BioRad, Hercules, CA, USA). The Mr standard proteins (14.4-116 kDa) were from Fermentas Inc. (Hoover, MD, USA); protein bands were stained with Coomassie Blue R-250. SDS-PAGE separations intended for preparing proteins to be digested in-gel and further characterized by LC-MS/MS were performed on precast 4-12% gradient polyacrylamide gels using an Invitrogen NuPage system (Carlsbad, CA, USA). Proteins bands were stained with Coomassie Blue G-250.
RNA extraction and reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted from rat mesentery, pancreas, kidney, liver, lung, heart, aorta and carotid using the Trizol reagent in RNAse-free labware, following the manufacturer instructions (Invitrogen, Carlsbad, CA, USA). RNA integrity was confirmed by agarose gel electrophoresis and then treated with DNAse for 15 min at room temperature to remove any potential genomic DNA contamination. Four micrograms of total RNA from each tissue, based on A 260 nm measurements, and oligo-d(T) were used to generate cDNAs by reverse transcription following SuperScript II protocols (Invitrogen). Cycling conditions consisted of an initial denaturation period of 2 min at 94 • C, followed by 40 three-step amplification cycles of 1 min denaturation at 94 • C, 1 min annealing carried out at 55 • C, 50 • C and 45 • C for CPA1, CPA2 and ␤-actin, respectively, terminating with an extension at 72 • C for 1.5 min. Samples were incubated for additional 30 min period at 72 • C (terminal elongation) after completion of the final cycle. For each set of primers, RT-PCR was performed on sterile water and RNA to check for contamination. Aliquots of 10 L of each PCR product were run on a 1% agarose gel, stained with ethidium bromide and subjected to densitometric scanning by ImageJ software (http://rsb.info.nih.gov/ij/); the intensity of each particular DNA was normalized to the respective ␤-actin PCR product and used as a measure of transcript expression.
Cloning and sequencing
The cloning and sequencing of cDNAs encoding CPA1 and CPA2 were carried out only with material derived from rat mesentery, the tissue from which we isolated the enzymes studied in the present work. The RNA extraction and RT were done as described in Section 2.6. The PCR reaction was performed using the Taq HiFi DNA polymerase (Invitrogen) using temperature cycling as described in Section 2.6.1. After PCR amplification the products were purified from the agarose gel using a DNA extraction kit (Fermentas) as instructed by the manufacturer. Purified PCR products from rat mesentery were inserted into a plasmid vector according to the manufacturer's instructions (TOPO TA Cloning ® Version K2, Invitrogen). Plasmids were transfected into Escherichia coli and the positive clones were identified after DNA digestion with specific restriction enzymes, Bam HI and XhoI for CPA1 and Sal I and Not I for CPA2. The digestion products were analyzed by agarose gel as described in Section 2.6.1 and the plasmids of the selected clones were purified (Promega, Madison, USA). Sequencing of 500 ng of DNA was done in both directions by the BigDye terminator chemistry with an ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA) using M13 Forward and M13 Reverse primers. Sequence similarities between each individual rat mesenteric CPA and other known proteins were searched using the BLAST program (http://www.ncbi.nlm.nih.gov/blast/).
Protein identification by tandem mass spectrometry
The bands of interest of SDS-PAGE gels were excised and the proteins therein were reduced, alkylated and digested in-gel with trypsin. LC-MS/MS experiments to identify the peptides of individual digestion mixtures were performed at the Tufts University Core Facility on a Thermo LTQ ion trap mass spectrometer after separation of peptides on C18 column and microelectrospray ionization. The instrument was set at needle voltage of 3 kV, resolution of 3 Da, collision energy of 30% and recurring ions were excluded. LC-MS/MS data were searched against the NCBI non-redundant protein database (ftp://ftp.ncbi.nih.gov/blast/db/FASTA/nr) using the SEQUEST algorithm for protein identification.
Results
Isolation and structural characterization of two major rat MAB perfusate carboxypeptidases A
We have previously shown that rat MAB perfusate contains five Ang-processing CPAs that are distinguishable by their chromatographic behavior, substrate specificity and sensitivity to inhibitors [25] . Two of these enzymes were chosen to be further characterized in the present work as major representatives of Ang I and Ang II-processing activities of the rat MAB perfusate.
Isolation of the rat MAB perfusate CPA1
As shown in Fig. 1A , an Ang-(1-7)-forming CPA was isolated by MonoQ anion-exchange chromatography from freshly prepared material analogous to that described as P4 in previous work [25] . This chromatographic step resulted in the purification of an enzyme to apparent homogeneity as judged by its migration during Partial nucleotide sequence of the cDNA encoding the rat mesenteric preproCPA1 and amino acid sequences of peptides derived from the major Ang-(1-7)-forming enzyme of the rat MAB perfusate. The sequences of the rat pancreatic preproCPA1 cDNA [27] (nucleotides 1-1260, primed numerals) and of the deduced amino acid sequence for the rat pancreatic preproCPA1 [27] (residues 1-419; NCBI GenBank ID: NP 058694.2) are shown for comparison. Sequence identity between the two polynucleotide chains is indicated by underlined bases in the pancreatic preproCPA1 cDNA sequence; note that the analogous nucleotide sequence comprising the segment between T650 and A723 of the pancreatic preproCPA1 cDNA has not been determined for the mesenteric cDNA. A single base change, C876T, corresponding to a silent mutation involving Ile 289 , is the only difference observed between the two sequences. The tryptic fragments Gly 277 -Lys 287 , Phe 279 -Lys 287 and Ser 335 -Lys 347 , indicated by boldface residues within the amino acid sequence of the pancreatic preproCPA1, were generated by in-gel digestion of the major Ang-(1-7)-forming enzyme of the rat MAB perfusate and characterized by de novo peptide sequencing via tandem mass spectrometry.
SDS-PAGE as a single component of molecular mass ca. 34 kDa (Fig. 1B) . This molecular mass value is consistent with that of the rat pancreatic CPA1 [27] , a protein whose sequence was also shown to contain segments which fully match those of tryptic fragments derived from the purified rat MAB perfusate Ang-(1-7)-forming CPA (Fig. 2) . The finding of such an active CPA1 in rat MAB perfusate, similar to the pancreatic enzyme, prompted us to investigate the existence and properties of the respective RNA message in the mesentery to broaden the comparison between the enzymes isolated from each of these tissues. The partial sequence of the cloned cDNA for the rat mesenteric enzyme was obtained as described in Section 2.6.2, resulting in a nucleotide sequence that shows correspondence between its deducible amino acid sequence and that of the rat pancreatic CPA1 [27] for all positions amenable to comparison in the alignment of Fig. 2 . Comparative analysis of cDNA sequences for rat CPA1 derived from pancreas [27] and mesentery (Fig. 2) indicated full identity between all 1184 nucleotides that could be actually compared except a C876T silent mutation for Ile 289 of the preproenzyme. Sequence data of the cDNA for rat mesenteric CPA1, shown in Fig. 2 , lack information corresponding to the segment from T 650 to A 723 of the archetypal pancreatic preproCPA1, a region that spans 46% of exon 6 and 33% of exon 7. This shortcoming occurred merely for technical reasons, namely the low resolution of the sequencing procedure observed for that region; in spite of this, the data presented in Fig. 2 indicate that all exons of the rat pancreatic CPA1 [4] are found in our sequence, suggesting that both the pancreatic and mesenteric forms of rat CPA1 followed identical splicing profile.
Isolation of the rat MAB perfusate CPA2
As shown in Fig. 3 , a second CPA was isolated from the rat MAB perfusate using a purification protocol resembling that described above for the Ang-(1-7)-forming CPA. A fresh P3 preparation, obtained as previously described [25] , was used as the starting material for the purification procedure, which yielded a single peak of CPA activity upon MonoQ anion-exchange chromatography (Fig. 3A) . Since we observed CPB activity overlapping the CPA activity peak in the MonoQ chromatography fractions, the pooled material from the CPA-rich fractions was applied to an arginine-Sepharose column for removal of this contaminant enzyme (Fig. 3B) , a process monitored by following the distribution of kininase activity along the eluting fractions. The resulting purified CPA preparation has two components of approximately 33.5 kDa and 115 kDa, as shown by SDS-PAGE (Fig. 3C,  lane 4) , whose identities were established as follows. MS/MS peptide mass fingerprint of in-gel tryptic digest of the excised 33.5 kDa molecular mass protein spot from the SDS-PAGE identified seven peptides, shown in Fig. 4 , which match the indicated segments of the described rat pancreatic CPA2 sequence [10] . Likewise, MS/MS peptide mass fingerprint of in-gel tryptic digest of the excised high molecular mass protein spot from the SDS-PAGE identified the peptides KGTDFQLNQLQGK, HTTIFEVLPQK, ASDSSINWNNLKGK, GDVAFVK, HQTVLENTNGK and DLLFRDDTK, which match the fragments 122-134, 226-236, 455-468, 547-553, 554-564 and 647-655, respectively, of the mature rat transferrin sequence (NCBI GenBank ID: BAA07548.1). As judged by the SDS-PAGE data of Fig. 3C , lane 4, transferrin is the only contaminant of our CPA2 preparation obtained from rat MAB perfusate; no attempts were made to rid the CPA2 preparation of this proteolytically inactive substance for the sake of recovery of CPA activity during the purification process. The finding of a functional CPA2 in the rat MAB perfusate, an enzyme which structurally resembles that isolated from pancreas [10] , led us to investigate the presence of the respective RNA message in the rat mesentery as an evidence of the local synthesis of the enzyme. The complete sequence of the cloned cDNA for the rat mesenteric preproCPA2 was obtained as described in Section 2.6.2, which turned out to be identical with that of rat pancreas [10] except for the base changes G177T, C439A and C1148G. The latter two changes introduced the mutations L147I and A383G (preproCPA2 numbering), indicating the polymorphic nature of this enzyme.
3.2. Proteolytic processing of Ang peptides by CPA1 and CPA2: relative rates of degradation of Ang I, Ang-(1-9), Ang II and Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) Whereas the rat MAB perfusate CPA1 was isolated as an Ang-(1-7)-forming enzyme using Ang II as the substrate for monitoring the activity during the chromatographic purification of the enzyme (Fig. 1A) , the isolation of the CPA2 was attained by measuring its activity toward Z-Val-Phe, a general purpose substrate for CPAs (Fig. 3A and B) . In spite of this, CPA2 was later shown capable The sample loaded onto the MonoQ column, prepared essentially as described in Fig. 2, peak 3 [25] , was the fraction of the perfusate that contained the major Ang-(1-9)-forming enzyme of pooled material from four isolated MABs. The column was equilibrated at room temperature with 20 mM Tris-HCl buffer, pH 8.1, and developed with 10 column volumes of a linear gradient of NaCl concentration (20-120 mM) in equilibrating buffer, at flow rate of 6 mL/min. Protein concentrations of the resulting fractions were estimated by A280 nm measurements and the respective enzymatic activities were assayed with Ang II as the substrate. The yield of this purification step was 55%, based on the recovery of the Z-Val-Phehydrolyzing activity. of hydrolyzing some Ang peptides with substrate specificity suggestive that differences between rat MAB CPA1 and CPA2 go beyond those observed during their isolations. These enzymes differentially process peptide components of the RAS such as Ang I, Ang II, Ang-(1-9) and Ang-(1-12), as shown in Figs. 5 and 6. For the sake of comparison between enzyme preference for different substrates, hydrolysis of each of these peptides was determined Nucleotide sequence of the cDNA encoding the rat mesenteric preproCPA2 and amino acid sequences of peptides derived from a major Ang-(1-9)-forming carboxypeptidase of the rat MAB perfusate. The sequences of the rat pancreatic preproCPA2 cDNA [10] (nucleotides 1-1254, primed numerals) and of the deduced amino acid sequence for the rat pancreatic preproCPA2 [10] (residues 1-417; NCBI GenBank ID: NP 001013101.2) are shown for comparison. Sequence identity between the two polynucleotide chains is indicated by underlined bases in the pancreatic preproCPA2 cDNA sequence. The base changes G177T, C439A and C1148G are the only differences observed between the two sequences, introducing the mutations L147I and A383G in the protein (preproCPA2 numbering). , indicated by boldface residues within the amino acid sequence of the pancreatic preproCPA2, were generated by in-gel digestion of a major Ang-(1-9)-forming CPA of the rat MAB perfusate and characterized by de novo peptide sequencing via tandem mass spectrometry. using a fixed amount of either enzyme (0.41 mU CPA1 and 1.02 mU CPA2, based on Z-Val-Phe hydrolysis), chosen so as to limit the cleavage of the substrate that was most rapidly degraded by the respective enzyme to about 80% of its initial concentration. Rat CPA1 is remarkable in which, under the assay conditions described in Fig. 5A , it is capable of generating Ang-(1-7) by a stepwise mechanism involving the sequential removal of the C-terminal residue of the intermediate products Ang-(1-9) and Ang II. This mechanism is rather corroborated by the results of the direct action of rat CPA1 on the substrates Ang II and Ang-(1-9), shown in Fig. 5B and C, respectively. Moreover, the accumulation of the intermediate Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) during the conversion of Ang I to Ang-(1-7) suggests that the cleavage of the C-terminal His residue of Ang-(1-9) may be the limiting step in the process. On the other hand, rat CPA2 generates only Ang-(1-9) upon incubation with Ang I (Fig. 6A) and, under the reaction conditions described in Fig. 6B and C, has a negligible, if any, action on Ang II and Ang-(1-9), respectively. In contrast to rat CPA1, CPA2 efficiently generates Ang I from Ang- (1-12) ; although this latter enzyme can further hydrolyze Ang I to Ang-(1-9), as seen in Fig. 6A , Ang I nevertheless accumulates in the reaction medium (Fig. 6D) . The CPA2-catalyzed conversion of Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) to Ang I proceeds through stepwise cleavage of C-terminal Tyr and Leu residues, as inferred from amino acid analysis of the respective reaction mixture (data not shown).
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All reactions mediated by both rat MAB CPA1 and CPA2, shown in Figs. 5 and 6, were fully inhibited by 10 M PCI or 1.0 mM 1,10-phenanthroline but not by 20 M soybean trypsin inhibitor (data not shown).
Kinetic analysis for the Ang II cleavage reaction
The inherent difficulties of measuring initial velocities for enzyme reactions in which products are further processed prevented us from determining kinetic constants for CPA-catalyzed hydrolysis of all Ang peptides tested except Ang II. The results of 6 . Cleavage of angiotensin peptides by CPA2 purified from rat MAB perfusate. Ang I, Ang II and Ang-(1-9) (0.25 mM each; panels A-C) and Ang-(1-12) (0.2 mM; panel D) were incubated at 37
• C for 30 min with 1.0 mU of CPA2 (Z-Val-Phe units) and the fragments formed identified by reversed phase HPLC. Note that the fragment Ang-(1-11) coelutes with substrate Ang-(1-12) under the analytical conditions used. Equimolar amounts of free Tyr and Leu were released from the substrate Ang-(1-12) upon incubation with CPA2 (measured by amino acid analysis; not shown). Fig. 7 indicate that the catalytic efficiency for the CPA1-catalyzed Ang II to Ang-(1-7) conversion reaction is two orders of magnitude higher than that mediated by CPA2, as judged by the k cat /K m values for the respective reactions. It should be noted that the rather small catalytic efficiency of CPA2 for the Ang II to Ang-(1-7) conversion reaction compelled the use of higher enzyme concentration, longer incubation times and larger reaction volumes, compared with the conditions described in Fig. 6B , in order to yield reliable initial velocity measurements for kinetic analysis presented in Fig. 7. 
Rat CPA1 and CPA2 mRNAs have peculiar tissue-specific expression
The expression of CPA1 and CPA2 mRNAs in some rat tissues was investigated by RT-PCR using specific CPA1 and CPA2 primers described in Table 1 and total RNA extracted from the indicated tissues (Fig. 8) . The PCR-amplified DNA fragments have sizes corresponding to those previously described for rat pancreatic preproCPA1, 1260 bp [27] , and preproCPA2, 1254 bp [10] . No PCR products were detected when sterile water was a substitute for the respective cDNA in the reaction (not shown). CPA1 mRNA was highly expressed in mesentery, pancreas, liver, lung and heart but was below detection level in kidney, aorta and carotid artery. A marked expression for CPA2 mRNA was detected in mesentery, liver, lung, pancreas, heart and carotid artery, but an expression just above detection level in kidney and aorta.
Discussion
The rat MAB perfusate contains different proteases [22] , among which carboxypeptidases that give rise to local bradykinin-and Ang-processing pathways [23, 25] . Two of the rat MAB perfusate carboxypeptidases that act on Ang peptides were purified and structurally characterized in the present work, revealing that the mesenteric vasculature produces CPA1 and CPA2 that are identical with their pancreatic counterparts as shown in Figs. 2 and 4 , respectively. Although both CPA1 and CPA2 are prototypical pancreatic enzymes with digestive functions [33] , their presence in the mesenteric vasculature suggests that they may constitute, along with other resident enzymes, local metabolic pathways for processing vasoactive peptides. Traditionally, only mast cell CPA and plasma CPU have been considered as regulatory enzymes within the M14 family of metallocarboxypeptidases [33] . More recently it was proposed that CPA6, an extracellular matrix protease secreted in some areas of human and mouse brains, plays a role in the regulation of neuropeptides [17] ; also, we have shown that the major kininase of the rat MAB perfusate is identical with rat CPB1 Table 1 . The expression level of mRNAs for CPA1 and CPA2 in the various tissues was estimated by densitometric scanning of the gels, normalized to the corresponding ␤-actin product, and expressed as CPA/␤-actin ratio in the column chart (C). Tissues are indicated as follows: Ki, kidney; Pa, pancreas; Li, liver; Lu, lung; Me, mesentery; He, heart; Ao, aorta; Ca, carotid artery.
[23], another prototypical pancreatic metallopeptidase. Thus, our present demonstration that rat MAB CPA1 and CPA2 are capable of processing Ang peptides extends the current evidence of the participation of metallocarboxypeptidases in regulatory pathways.
The peculiar proteolytic profiles displayed by CPA1 and CPA2 toward Ang peptides probably reflect the proposed evolutionary events that have allowed these enzymes to diverge from one another with respect to substrate specificity, resulting in overlapping and complementary preferences [10] . Thus, Ang I was efficiently acted upon by CPA1, forming Ang-(1-7) by a three-step pathway with Ang-(1-9) and Ang II as intermediates (Fig. 5A) ; confirmatory evidence of this sequential mode of action of CPA1 has been provided by the formation of the end-product Ang-(1-7) in analogous reactions when either Ang-(1-9) or Ang II, the intermediates in the conversion of Ang I to Ang-(1-7), were used as substrate for the enzyme (Fig. 5B and C) . On the other hand, only Ang-(1-9) was released upon incubation of Ang I with CPA2 (Fig. 6A) ; in agreement with this result, the substrates Ang II and Ang-(1-9) were negligibly hydrolyzed by CPA2 under the conditions described in Fig. 6B and C. Comparison of the catalytic efficiencies of the CPA1-and CPA2-mediated conversions of Ang II to Ang-(1-7) indicates a value approximately 200-fold higher for the former enzyme (Fig. 7) , consistent with the results of Ang II cleavage by these enzymes shown in Figs. 5 and 6B; such a discrepancy between kinetic parameters of CPA1 and CPA2 toward Ang II is significantly larger than those observed for synthetic substrates having carboxyl-terminal Phe residue [10] , the same terminal residue of Ang II. It should also be noted here that the K m value for the CPA1-catalyzed conversion of Ang II to Ang-(1-7), as determined in Fig. 7 , is of the same order of magnitude as that of the analogous reaction catalyzed by ACE2 [28] , a carboxypeptidase for which there is compelling evidence of participation in the RAS [34] ; thus, the binding affinity of rat CPA1 for Ang II seems compatible with the participation of this enzyme in the formation of Ang-(1-7) under physiological conditions. However, the contribution of CPA1 to the in vivo generation of Ang-(1-7) in the rat mesenteric vascular bed is likely to depend on factors beyond that of the enzyme affinity for Ang II, among which the actual CPA1 activity and the presence of circulating carboxypeptidase inhibitors. Assuming that CPA1 is the major enzyme responsible for the Ang II to Ang-(1-7) conversion reaction in the rat MAB perfusate, as inferred from the present work (Figs. 1A and 5B), a rat MAB secretes on average an amount of this enzyme, per second, capable of processing over 50 pmol Ang II per min under conditions prevailing in the in vitro enzyme assay [25] ; although such CPA1 activity is large enough to metabolize significant amounts of Ang II, it should be borne in mind that protease inhibitors and degradation of the enzyme may check the enzyme activity under in vivo conditions. Thus, the possible involvement of CPA1 in the mesenteric vascular bed RAS and the relative contribution of this enzyme to the local generation of Ang-(1-7) need to be established. Another striking difference between the proteolytic specificities of rat MAB CPA1 and CPA2 was revealed using Ang-(1-12) as a substrate; as shown in Figs. 5D and 6D, Ang-(1-12) was a far better substrate for CPA2 than for CPA1, notwithstanding their nearly identical efficiencies to cleave the carboxyl-terminal Tyr residue from a model synthetic peptide [10] . These findings regarding substrate preferences of CPA1 and CPA2 suggest that structural features that determine substrate specificity of these enzymes go beyond the terminal residue. On account of the in vitro capability of CPA1 and CPA2 to form biologically active Ang I-derived peptides, namely, Ang-(1-9), Ang II and Ang-(1-7), as observed in Figs. 5 and 6, these enzymes can, therefore, be regarded as potential regulators of local RAS in the rat mesenteric vasculature. Among the peptides processed by rat MAB CPA1 and CPA2, Ang II has been traditionally viewed as the central effector molecule of the RAS, whose actions on the cardiovascular system and tissue proliferation are mediated mainly by the Ang type-1 (AT1) receptor and also by AT2 receptor, which opposes at least some of the effects of AT1 stimulation [2, 7] . Ang-(1-9) is an endogenous ACE inhibitor [13, 29] and precursor of Ang-(1-7) [16, 28] , while this latter heptapeptide participates in distinct regulatory processes of the cardiovascular function by stimulating a receptor of its own, the Mas receptor [7] . The ability of CPA2 and, to a much lesser extent of CPA1, to generate Ang I from Ang-(1-12), as shown in Figs. 5D and 6D, is remarkable in that it creates a pathway for utilization of this recently identified putative component of the RAS. Ang-(1-12) is thought to be directly derived from angiotensinogen by a renin-independent process, being a highly abundant Ang peptide in several rat tissues [20] . The processing of this dodecapeptide into shorter Ang peptides has been demonstrated under different experimental conditions, suggesting the participation of ACE [1, 31] , chymase [26] and neprilysin [31] in the formation of Ang I, Ang II and Ang-(1-7), respectively. Ang-(1-12) is found in its highest levels in extracts of rat intestine [20] , a tissue whose vessels can secrete CPA2, an efficient in vitro Ang-(1-12)-metabolizing enzyme (Fig. 6D) ; any functional correlation between CPA2 and Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) in the rat MAB and other organs remains to be established, particularly in view of the demonstration that the routes for Ang-(1-12) metabolism in plasma and tissue extracts correlate with their contents of ACE and neprilysin [3] .
In addition to purifying and characterizing the CPA1 and CPA2 from rat MAB in this work, we also investigated the expression of the respective mRNAs in some other rat tissues. Gene transcripts for CPA1 and CPA2 of about 1.26 kb were detected at different levels in some of the rat tissues investigated (Fig. 8) , indicating that a secretable form of these enzymes, of the same size of their respective pancreatic counterparts, are expressed in various tissues. In a previous report [21] , it was described that a single CPA1 mRNA, identical with that of the pancreatic CPA1, is also expressed in rat brain, heart, stomach and intestine at low levels, suggesting a selective expression of the enzyme in restricted cell populations of these tissues. On the other hand, the CPA2 mRNA was reported to be expressed in rat brain, lung and testis as a shortened CPA2 transcript, produced presumably by alternative splicing of the CPA2 pro-mRNA, that differs from the full-length pancreatic transcript by deletion of a sequence that encodes the signal and activation peptides of the pancreatic preproenzyme; as predicted by the sequence of this shortened mRNA, rat brain CPA activity was shown to be associated with a cytosolic CPA2 lacking the signal and activation peptides, whose enzymological and inhibitory properties differ from those of the full-length CPA2. The display of such an altered enzyme activity associated with a particular subcellular localization of this shortened CPA2 has led to the suggestion that this enzyme plays a role distinct from that fulfilled by CPA2 in protein digestion [21] . It is worth stressing that, in the present work, we detected only an mRNA for CPA of about 1.26 kb in the rat lung (Fig. 8) , corresponding to the full-length pancreatic enzyme. Since the oligonucleotide primers we used for detection of the cDNA encoding the rat CPA2 (Table 1) would not amplify the cDNA of the shortened rat CPA2 described by Normant et al. [21] , the possibility remains that rat lung expresses both the cytosolic and secreted isoforms of CPA2.
Based on the extrapancreatic distribution of the rat CPA1 and CPA2 (Fig. 8 ) and on the peculiar proteolytic specificities of these enzymes (Figs. 5 and 6 ), we suggest that, in spite of their being structurally identical with the respective digestive pancreatic counterparts, they may be directly involved with local processing of Ang peptides and other so far unidentified peptides in the vasculature of different tissues. Indeed, the suggestion that rat CPA1 and CPA2 may participate in the processing of Ang peptides finds support in an earlier report of the expressive production of Ang-(1-9) in the rat kidney by an unspecified CPA-like enzyme that localizes to the mesangial glomerular cells and adventitia of kidney blood vessels [11] . From the functional standpoint, the contribution of CPA1 and CPA2 to the local metabolism of Ang peptides is likely to depend on the repertoire of proteolytic enzymes of a particular tissue or, else, on the suppression of competing pathways for the degradation of a particular Ang peptide by therapeutic or endogenous inhibitors. For instance, the major Ang I-derived metabolite formed by human heart homogenate in the presence of interstitial fluid was not Ang II but Ang-(1-9), because the Ang II-forming enzymes chymase and ACE were suppressed by endogenous inhibitors to which the carboxypeptidases of human heart were refractory [13] .
In conclusion, we hypothesize that rat CPA1 and CPA2, in addition to their well established function as digestive enzymes [33] , belong to the RAS for their possible participation in the circulating and cellular network interconnected by enzyme-catalyzed reactions leading to the formation of Ang II and other Ang I-derived biologically active peptides.
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